Search
for
Sort by
Research 901–930 of 1000+
- Abstract 14
- Telocytes of the male reproductive system: dynamic tissue organizers
- Improvement of cell proliferation and antioxidant activity of silymarin in hair follicles dermal papillae isolated from the human scalp: Comparison with vitamin C effects
- What are the possible reasons for urethral PSA varieties after radical prostatectomy?
- The dental needs of children with Epidermolysis Bullosa and service delivery: a scoping review
- Cancer Chemotherapy: an Introduction
- Alopecia Areata and malignancies: uncertainties clarified by a large-scale population-based study
- Beeinflussen Medikamente gegen das benigne Prostatasyndrom Stimmung oder Kognition?
- Synthesis and structural characterization of a new dinuclear platinum(III) complex, [Pt<sub>2</sub>Cl<sub>4</sub>(NH<sub>3</sub>)<sub>2</sub>{μ-HN=C(O)Bu<sup>t</sup>}<sub>2</sub>]
- Case Report: Disorder of Sexual Development in a Chinese Crested Dog With XX/XY Leukocyte Chimerism and Mixed Cell Testicular Tumors
- Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men
- Pseudoglucagonoma syndrome secondary to pancreatitis: A case report
- Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese
- Are ABO/Rh blood groups A risk factor for polycystic ovary syndrome?
- 46, XY 5-Alpha Reductase Deficiency in a 36-Year-Old Phenotypic Female Patient
- Review of Topical Therapies for Beard Enhancement
- Bilateral nevus comedonicus of the eyelids: An unusual cause of ptosis and ectropion
- A randomized double blind controlled study evaluating efficacy & Safety of vatika enriched coconut hair oil on hair health in women with hair fall and dandruff
- Editorial Comment
- Finasterid in der Behandlung der benignen Prostatahyperplasie
- Basic research in biostimulation
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Case Report: Pulsed electric field treatment of metastatic liver disease demonstrating a possible abscopal response
- Evaluation of a Porcine-Derived Placental Powder Treatment for Skin Wound Healing in an In Vivo Rat Skin Defect Model.
- Validation of Finasteride Tablets USP by HPLC Isocratic with UV Detector
- Macrophage Activation Syndrome/Secondary Hemophagocytic Lymphohistiocytosis in Adult‐Onset Still's Disease: An Uncommon Initial Presentation in a Young Nepalese Female: A Case Report
- P447: Late onset biotinidase deficiency misdiagnosed as neuromyelitis optica: A case report and review of diagnostic challenges
- Exploring the Systematic Anticancer Mechanism in Selected Medicinal Plants: A Review
- Chemistry, Pharmacology and Therapeutic Potential of Decursin: A Promising Natural Lead for New Drug Discovery and Development